Author

A Kang

Observed name: A. Kang

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Bristol-Myers Squibb (United States), Pacira (United States), Bristol-Myers Squibb (United Kingdom)

ORCID: 0009-0006-3215-1235

Observed ORCID: 0009-0006-3215-1235

OpenAlex ID: A5090154792

Retrospective Database Analysis of Hospital Length of Stay, Discharge Location, And Readmissions Among Patients Undergoing Total Knee Arthroplasty (TKA) In The United States

2016 · A Kang, S Dagenais, et al. · Value in Health · 1

Impact of Bupivacaine Liposomal Injectable Suspension on Hospital Length of Stay and Home Discharge among Medicare Patients Undergoing Total Knee Arthroplasty

2016 · S Dagenais, A Kang, et al. · Value in Health · 1

PDF

Examining Length of Stay and Home Discharge when Using Bupivacaine Liposomal Injectable Suspension in Medicare Patients Undergoing Total Hip Arthroplasty

2016 · S Dagenais, A Kang, et al. · Value in Health · 1

A Comparison of Total Hospitals Costs for Medicare Patients Undergoing Total Knee Arthroplasty With or Without Bupivacaine Liposomal Injectable Suspension

2016 · S. Dagenais, A. Kang, et al. · Value in Health · 1

PDF

Clinical outcomes following atrial fibrillation diagnosis in routine practice: a nationwide cohort study in Sweden

2026 · K A Smith, P Sandin, et al. · European Heart Journal

PDF

PCR56 Are Limitations in Physical Function Relevant and Important Concepts To Assess in Patients on Antithrombotic Therapy for Cardiovascular Conditions?

2024 · KW Wyrwich, A Clark, et al. · Value in Health

PDF

CO156 Direct Oral Anticoagulants in Adults with Non-Valvular Atrial Fibrillation: Systematic Review and Network Meta-Analysis of Real-World Evidence

2023 · R. Subash, S. Lister, et al. · Value in Health

PDF

Real-world assessment of antiplatelet treatment therapies for acute coronary syndrome (ACS) patients in the United States in a nationwide Electronic Health Record in 2018-2020

2023 · A Kang, J Jiang, et al. · European Heart Journal

PDF

Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation

2023 · S Deitelzweig, A Kang, et al. · European Heart Journal

PDF

HSD82 Real-World Assessment of Antiplatelet Treatment Therapies for Patients With Acute Coronary Syndrome (ACS) in the United Kingdom

2022 · A Kang, J Jiang, et al. · Value in Health

Real-world assessment of anti-platelet therapies for recurrent stroke prevention in non-atrial fibrillation Japanese patients after recent ischemic stroke or transient ischemic attack

2022 · A Kang, J Jiang, et al. · European Heart Journal

PDF

Heart failure across the range of preserved ejection fraction in United States clinical practice

2022 · S Greene, J A Spertus, et al. · European Heart Journal

PDF

Time at home among nonvalvular atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: an ARISTOPHANES analysis

2021 · S Deitelzweig, A Keshishian, et al. · European Heart Journal

PDF

Time at home among nonvalvular atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants versus warfarin

2021 · S Deitelzweig, A Keshishian, et al. · European Heart Journal

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin among nonvalvular atrial fibrillation patients with prior bleeding events

2021 · G.Y.H Lip, A Keshishian, et al. · European Heart Journal

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants among nonvalvular atrial fibrillation patients with prior bleeding events

2021 · G.Y.H Lip, A Keshishian, et al. · European Heart Journal

P4768Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients with differential duration of treatment: an analysis of the ARISTOPHANES study

2019 · S Deitelzweig, A Keshishian, et al. · European Heart Journal

P4794Comparative effectiveness and safety of non-VKA oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients with differential treatment duration: an ARISTOPHANES study analysis

2019 · S Deitelzweig, A Keshishian, et al. · European Heart Journal

P3346Validation of obesity coding among newly-treated nonvalvular atrial fibrillation patients using an integrated electronic medical record and claims database

2019 · R Jain, A Watzker, et al. · European Heart Journal

Pcv14 an Appraisal of Real-world Evidence (rwe) in Patients With Non-valvular Atrial Fibrillation (nvaf) Treated With Non-vitamin K Antagonist Oral Anticoagulants (noacs)

2019 · S. Deitelzweig, A. Cichewicz, et al. · Value in Health

PDF

Pcv97 Economic Value of Non-vka Oral Anticoagulants (noac) in Non-valvular Atrial Fibrillation (nvaf): a Literature Review of Global Health Technology Assessments (hta)

2019 · R.D. Lopes, S. Berger, et al. · Value in Health

Comparison of Total Hospital Charges and Costs Using Chargemaster Data From Premier for Medicare Patients Undergoing Total Hip Arthroplasty

2016 · S. Dagenais, A. Kang, et al. · Value in Health

PDF

Use and Impact of Multimodal Analgesia in Total Joint Arthroplasty

2016 · J. Aggarwal, S. Park, et al. · Value in Health

Estimated Cost of Bupivacaine Liposomal Injectable Suspension in Medicare Patients Undergoing Total Hip Arthroplasty Using Premier Chargemaster Data

2016 · S. Dagenais, A. Kang, et al. · Value in Health

Estimating Hospital Costs for Bupivacaine Liposomal Injectable Suspension in Medicare Patients Undergoing Total Knee Arthroplasty Using Premier Chargemaster Data

2016 · S. Dagenais, A. Kang, et al. · Value in Health

Works count: 28

Citation count: 4

H-index: 1

I10-index: